Document |
Document Title |
WO/2013/062105A1 |
Provided is an affinity carrier having a low pressure loss and a high binding capacity, even when the linear flow rate of a solution passing through the carrier is fast. Also provided is a silica spherical body having (a) according to la...
|
WO/2013/056377A1 |
The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.
|
WO/2012/154735A9 |
The present compositions and methods relate to a thermostable carbonic anhydrases, polynucleotides encoding the carbonic anhydrase, and methods of make and/or use thereof. Formulations containing the carbonic anhydrase are suitable for u...
|
WO/2013/039190A1 |
The purpose of the present invention is to provide a polypeptide-containing polymer that can be used to manufacture an antimicrobial fiber. The purpose of the present invention is also to provide a method for polypeptide immobilization o...
|
WO/2013/038158A1 |
The disclosure relates to a magnetic particle comprising: a ligand that specifically binds an intracellular antigen, a cell membrane penetrating cationic peptide and a peptide comprising an amino acid sequence that is adapted to interact...
|
WO/2013/033838A1 |
Liposomal formulations of cationic peptides and anionic liposomes are provided. The liposomal formulations comprise a diagnostic or therapeutic cationic peptide associated with liposomes comprising one or more anionic lipids. Methods of ...
|
WO/2012/173422A9 |
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-p...
|
WO/2012/172347A9 |
A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample o...
|
WO/2013/029180A1 |
It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective a...
|
WO/2013/029182A1 |
It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutical...
|
WO/2013/029472A1 |
Provided is a composition for extracting unrelated circulating nucleated cells from the peripheral blood of a diseased animal model, comprising the composition kit. The composition consists of the following ingredients: buffer solution, ...
|
WO/2013/033359A1 |
Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analy...
|
WO/2013/027796A1 |
Provided is a peptide capable of binding to human IgG specifically or selectively. A peptide characterized by comprising an amino acid sequence represented by formula (I): (X1-3)-C-(X2)-H-R-G-(Xaa1)-L-V-W-C-(X1-3) (wherein Xs independent...
|
WO/2007/025388A9 |
Single-domain antibodies that bind pro-apoptotic proteins Bax and caspase-3 are identified and isolated. These single-domain antibodies may be used to modulate the activity of Bax and caspase-3, thereby modulating the symptoms and steps ...
|
WO/2013/025052A2 |
The present invention relates to a bioactive carbon nanotube composite functionalized with a β-sheet polypeptide block copolymer which shows excellent water dispersion, and has biological activity so as to be used as a stimulus-reactive...
|
WO/2013/018880A1 |
The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly...
|
WO/2013/010225A1 |
The present invention relates to enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention relates to variants of the OpdA enzyme from Agrobacterium that display improved activity when compared to the na...
|
WO/2013/002449A1 |
Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epito...
|
WO/2012/177775A1 |
The invention provides methods for delivery of payloads to targets in samples using non-sterically hindered complexes. The invention further provides reagents and kits for practicing the methods of the invention. The invention also provi...
|
WO/2012/172342A2 |
A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemok...
|
WO/2012/172337A2 |
A method for treating cardiovascular disease comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
WO/2012/172336A2 |
A method for treating inflammatory skin disease comprises applying peripheral blood from a patient to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine ...
|
WO/2012/172339A2 |
A method for treating inflammatory arthritis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
WO/2012/172343A2 |
A method for treating primary sclerosing cholangitis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding...
|
WO/2012/171429A1 |
Disclosed are a polyethylene glycol-interferon conjugate, a preparation method thereof, and a pharmaceutical composition containing a therapeutically effective amount of the interferon conjugate and use thereof in the preparation of anti...
|
WO/2012/172346A2 |
A method for treating a respiratory conditions comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ...
|
WO/2012/172344A2 |
A method for treating sepsis and/or respiratory distress syndrome (RDS) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of s...
|
WO/2012/172340A2 |
A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent c...
|
WO/2012/172345A2 |
A method for treating an allergic condition comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine rece...
|
WO/2004/070015A9 |
|
WO/2012/159171A1 |
The present invention relates to complexes of silica-containing materials and peptide linkers for the capture of biological and chemical entities. In particular, the present invention relates to the use of complexes of silica-containing ...
|
WO/2012/159170A1 |
The present invention relates to methods of capturing biological and chemical entities indirectly or directly bound to a peptide linker. In particular, the present invention relates to the use of silica-containing materials to capture bi...
|
WO/2012/157339A1 |
This growth factor anchoring type bone graft material is characterized in that growth factor containing collagen-binding sites, which contains growth factor receptor agonist peptides and collagen-binding peptides, is bonded to a bone gra...
|
WO/2012/158445A1 |
The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal...
|
WO/2012/142659A1 |
The present invention relates to methods and reagents for use in site-selective modification of proteins and other entities with functionalized peptides using a chemoenzymatic sortase mediated reaction. The functionalized entities may be...
|
WO/2012/142362A2 |
A synthetic platelet includes a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, the peptides including a plurality of von Willebrand factor-binding peptides (VBPs)...
|
WO/2012/139208A1 |
The present invention relates to a methods and composition in which a D-form or retro-inverso Pseudomonas pilin peptide, optionally having a polyethylene glycol moiety covalently attached to the peptide, is bound to a substrate. The disc...
|
WO/2012/141554A2 |
The present invention relates to a complex in which an anti-cotinine antibody is bound to a binder material comprising a binding substance and cotinine, and relates to a use therefor. The binder material according to the present inventio...
|
WO/2012/138429A1 |
The present invention concerns molecularly imprinted polymers (MIPs) having an affinity for natriuretic peptides, such as atrial natriuretic peptide (ANP). In some embodiments, the M I P is a nanoparticle (a molecularly imprinted polymer...
|
WO/2012/135959A1 |
Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained vi...
|
WO/2012/131504A1 |
The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide containing a phosphorylation site (with or without phosphorylation of the site) linked to an immunogenic carrier for the prevention,...
|
WO/2012/133349A1 |
The present invention addresses the problem of developing a technique for producing a novel modified protein ligand that maximizes binding capacity and binding efficiency with respect to a target molecule when said ligand is immobilized ...
|
WO/2012/126788A1 |
An oligopeptide microarray and methods for the synthesis thereof are presented. Further presented is a microarray on a solid support comprising at least about 10,000 oligopeptide features per cm2 and preferably at least about 50,000 olig...
|
WO/2012/122860A1 |
Disclosed is a recombinant human insulin or analog conjugate thereof. Said conjugate is formed by connecting the ε-amino group of lysine 29 of the B chain to activated polyethylene glycol by means of an amide bond. Further disclosed is ...
|
WO/2012/121740A1 |
Provided are Manufacturing and Purification Processes of Complex Proteins found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and their application.
|
WO/2012/118388A1 |
The present invention discloses a method of assaying Fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a F-S-L peptide- lipid constr...
|
WO/2012/116439A1 |
A method for making a biomaterial comprising providing at least one polypeptide fraction chymotryptically isolated and extracted from fibroin, and adding the at least one extracted polypeptide fraction to a hydrogel precursor before gell...
|
WO/2012/112767A2 |
This invention relates to compositions comprising collagen binding peptides coupled to nanoparticles. The invention also relates to a method of imaging a collagenous matrix using a composition comprising collagen binding peptides coupled...
|
WO/2012/109977A1 |
The present invention provides a human serum or plasma protein complex and the separation spectrum thereof, and the uses thereof in inflammation and/or immune-related chronic disease screening and/or prognosis evaluation, and medicinal e...
|
WO/2012/109553A2 |
Novel CH2 domain template molecules wherein donor loops from a database of domains are transferred to a CH2 domain scaffold. At least one or up to three loops from a donor are transferred to the CH2 domain. The donor loops may be chosen ...
|